Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, +239

The Lancet

Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment +4

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He, +20

New England Journal of Medicine

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard, +27

The Lancet Oncology

Checkmate 063Single-arm TrialMedicineImmunologyImmune Checkpoint Inhibitor +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, +247

The Lancet Oncology

Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment +4

Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC

Masahiro Tsuboi, Roy S. Herbst, Thomas John, +17

New England Journal of Medicine

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter, +102

The Lancet Respiratory Medicine

Antifibrotic TherapyAdvanced Lung DiseaseIdiopathic Pulmonary FibrosisPulmonary PharmacologyPulmonary Fibrosis +4

Modulation of Antioxidant Enzyme Expression and Function by Estrogen

Kerstin Strehlow, Simone Rotter, Oliver Adam, +4

Circulation Research

Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway

Stefan Kahlert, Simone Nuedling, Martin van Eickels, +3

Journal of Biological Chemistry

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry

Marius M. Hoeper, Dörte Huscher, Hossein Ardeschir Ghofrani, +25

International Journal of Cardiology

HypertensionHeart FailureCompera RegistryPulmonary CareCardiovascular Disease +11

Estrogen Modulates AT₁Receptor Gene Expression In Vitro and In Vivo

Georg Nickenig, Anselm T. Bäumer, Christian Grohé, +9

Circulation